Drug or technology

Ketamine

3 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

AUG 17, 2026 · PHASE 2 TRIAL

Electrophysiologic Mechanisms of Ketamine Antidepressant Response

ClinicalTrials.gov

Phase 2 mechanistic study in a highly selected population (epilepsy patients with intracranial electrodes) examining electrophysiologic biomarkers of ketamine response; no results yet reported in this registry record.

PreliminaryNCT07768618 Depressive Symptoms Ketamine

Reported

Planned enrollment37

PhasePhase 2

Ketamine dose0.5 mg/kg over 40 minutes

AUG 13, 2026 · PHASE 3 TRIAL

InTRavenous kEtAmine and immerSive virtUal Reality to Treat dEpression

ClinicalTrials.gov

This is a Phase 3 pilot feasibility study with no results yet reported; it is designed to test recruitment and retention, not to establish efficacy, and enrollment is small and still recruiting.

PreliminaryTreatment Resistant Depression Sunnybrook Health Sciences Centre Ketamine

Reported

Estimated enrollment31

Primary outcome measure 1Number of participants who complete at leas…

Primary outcome measure 2Time required to complete enrolment at time…

AUG 13, 2026 · PHASE 1 TRIAL

Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder

ClinicalTrials.gov

This is a Phase 1 interventional trial registration with no posted results; it describes a planned study of ketamine neuropharmacodynamics in depression using imaging biomarkers, still in recruitment.

PreliminaryCobot TS MV robotic arm for TMS NCT03065335 NeurOptics PLRTM-30000 Pupillometer

Reported

Planned enrollment150

Study phasePHASE1

Ketamine dose (primary outcome)0.5 mg/kg over 40 minutes